Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

Christina M. Annunziata, Amanda J. Walker, Lori M. Minasian, Minshu Yu, Herbert L. Kotz, Bradford J. Wood, Katherine R. Calvo, Peter L. Choyke, Daniel Kimm, Seth M. Steinberg, Elise C. KohnClinical 2010 · DOI

Abstract

Vandetanib 300 mg daily monotherapy had no significant clinical benefit in this disease setting. Proteomic analysis of paired biopsies detected both phosphorylated-EGFR and phosphorylated-VEGF receptor-2 in ovarian tumor tissue, but only phosphorylated-EGFR was measurably inhibited by vandetanib.
BibTeX
@inproceedings{annunziata2010vandetanib,
  author = {Christina M. Annunziata and Amanda J. Walker and Lori M. Minasian and Minshu Yu and Herbert L. Kotz and Bradford J. Wood and Katherine R. Calvo and Peter L. Choyke and Daniel Kimm and Seth M. Steinberg and Elise C. Kohn},
  title = {{Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2}},
  booktitle = {Clinical},
  year = {2010},
  doi = {10.1158/1078-0432.ccr-09-2308},
}

Loading related content...

Figure